The doctrine of inherent disclosure is not one of the more common methods for invalidating patent claims, but this doctrine led the U.S. Court of Appeals for the Federal Circuit to declare that several claims found in a patent held by Carl Zeiss X-Ray Microscopy Inc. are invalid.
University of Health Sciences and Pharmacy in St. Louis has described estrogen-related receptor α (ERR) modulators reported to be useful for the treatment of diabetes, amyotrophic lateral sclerosis, heart failure, breast cancer, renal disorders, metabolic diseases, Alzheimer’s disease and Parkinson’s disease, among others.
Monte Rosa Therapeutics Inc. has divulged molecular glues as cyclin-dependent kinase 2 (CDK2) degradation inducers reported to be useful for the treatment of cancer and amyloidosis.
Mayo Foundation for Medical Education and Research (MFMER) and University of Florida have identified atrial natriuretic peptide B (NPR2; guanylate cyclase B) receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of fibrosis.
University of Michigan has disclosed prodrugs of stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorder and infections.
Otsuka Pharmaceutical Co. Ltd. has described macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) inhibitors reported to be useful for diagnosis and treatment of pain, infections, amyotrophic lateral sclerosis, multiple sclerosis, cardiovascular disorders, Alzheimer’s disease and Parkinson’s disease, among others.
Eli Lilly & Co. has divulged aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of psoriasis, atopic dermatitis, ulcerative colitis, Crohn’s disease, graft-versus-host disease, rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis.
Bpgbio Inc. has synthesized bifunctional compounds comprising an E2 ubiquitin ligase binding ligand covalently linked to an estrogen receptor α (ER-α; ESR1) targeting moiety through a linker acting as ESR1 degradation inducers reported to be useful for the treatment of cancer.
RSS
